Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in India

AIDS Research and Therapy

Volumn 9, Issue , 2012, Pages

  Thakar, Madhuri ^a   Mahajan, Bharati ^a   Shaikh, Nawaj ^a   Bagwan, Salman ^a   Sane, Suvarna ^a   Kabra, Sandhya ^b   Rewari, Bharat ^b   Shaukat, Mohamad ^b   Singh, Namita ^c   Trevor, Peter ^c   Paranjape, Ramesh ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b National AIDS Control Organization   (India)

^c CLINTON HEALTH ACCESS INITIATIVE   (United States)

Author keywords

CD4+ T cell count; HIV; PIMA CD4 analyzer; Point of care

Indexed keywords

ADULT; ANALYZER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HEALTH CENTER; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; POINT OF CARE TESTING; PRICK TEST; PRIORITY JOURNAL; TRAINING;

EID: 84866513607     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-9-26     Document Type: Article

References (15)

1. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach 2010, http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, World Health Organization.
2. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008, 371:1443-1451. 10.1016/S0140-6736(08)60624-8, 18440426.
3. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009, 23:335-342. 10.1097/QAD.0b013e328321823f, 19114870.
4. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. When To Start Consortium: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-1363. 2670965, 19361855.
5. UNAIDS Report on the global AIDS epidemic 2010, http://www.unaids.org/globalreport/Global_report.htm, UNAIDS.
6. Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K. Performance Evaluation of the Alere PIMA CD4 Test for Monitoring HIV-Infected Individuals in Resource-Constrained Settings. J Acquir Immune Defic Syndr 2011, 58(2):141-147. 10.1097/QAI.0b013e31822866a2, 21709568.
7. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, Hatzold K, Mangwiro A, Bhattacharya G, Lehe J, Peter T. Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr 2010, 55(1):1-7. 10.1097/QAI.0b013e3181e93071, 20622679.
8. Papa Alassane D, Géraldine D, Abdoul Aziz C, Birahim Pierre N, Djibril W, Makhtar CamaraSouleymane M, Luc K, Tandakha Ndiaye D. Multisite Evaluation of a Point-of-Care Instrument for CD4+ T-Cell Enumeration Using Venous and Finger-Prick Blood: The PIMA CD4. J Acquir Immune Defic Syndr 2011, 58:103-111.
9. Pattanapanyasat K, Phuang-Ngern Y, Sukapirom K, Lerdwana S, Thepthai C, Tassaneetrithep B. Comparison of 5 flow cytometric immunophenotyping systems for absolute CD4+ T-lymphocyte counts in HIV-1-infected patients living in resource-limited settings. J Acquir Immune Defic Syndr 2008, 49(4):339-347. 10.1097/QAI.0b013e31818c1721, 19186347.
10. Zijenah LS, Kadzirange G, Madzime S, Borok M, Mudiwa C, Tobaiwa O, Mucheche M, Rusakaniko S, Katzenstein DA. Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. J Transl Med. 2006, 4:33. 10.1186/1479-5876-4-33, 1586214, 16907973.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
12. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, Lehe JD, Peter TF. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 2011, 25:807-812. 10.1097/QAD.0b013e328344f424, 21378535.
13. Annual Report, 2010-11. National AIDS Control Organization Department of AIDS Control, Ministry of Health & Family Welfare Government of India http://www.nacoonline.org/upload/REPORTS/NACO%20Annual%20Report%202010-11.pdf, Annual Report, 2010-11. National AIDS Control Organization.
14. Bachani D, Garg R, Rewari B, Hegg L, Rajasekaran S, Deshpande A, Emmanuel K, Polin C, Rao S. Two-year treatment outcomes of patients enrolled in India's national first-line antiretroviral therapy programme. Natl Med J India 2010, 23(1):7-12.
15. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, Lehe JD, Peter TF. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet Published online September 26, 2011.